Table 4 Clinical diagnosis and treatment parameters

Hysterectomy for non-HPV-related conditions, % per year [93]

   15–24 years

   25–29 years

   30–34 years

   35–39 years

   40–44 years

   45–54 years

   ≥ 55 years

Cervical cytology screening, % per year (excluding those with hysterectomy) [47]

   10–14 years

   15–19 years

   20–24 years

   25–29 years

   30–34 years

   35–39 years

   40–44 years

   45–49 years

   50–54 years

   55–59 years

   60–64 years

   65–69 years

   70–74 years

   75–79 years

   80–84 years

   85+

Women never screened, %

Liquid-based cytology sensitivity, %

   for CIN 1 [114]

   for ≥ CIN 2/3 [115]

Liquid-based cytology specificity, % [114, 115]

Colposcopy sensitivity, % [117]

Colposcopy specificity, % [117]

Symptom development, % per year

   for LCC

   for RCC

   for DCC

Eradication with treatment, %

   for CIN1 [118–124]

   for CIN2 [118, 122, 124, 125]

   for CIN3 [118, 122, 124, 125]

   for LCC [89]

   for RCC [89]

   for DCC [89]

   for anogenital warts [41]

Persistence of HPV following eradication of CIN, % [127]

Persistence of HPV following eradication of cervical cancer, % [129]

Persistence of HPV following eradication of genital warts

Anogenital wart patients seeking physician care, % [71]